Approximately half of the serum samples from the breast cancer patients had detectable levels of serum VEGF, however, no significant difference (P=0.75) in the VEGF levels were observed between the two patients groups: NSR and REC (Figure 2F). This evidence concerns the gene VEGFA and breast carcinoma.